RecruitingNCT07815886

Benralizumab Effectiveness in EGPA

Benralizumab Effectiveness in the LONG-term Real-life Setting in EGPA: The BELONG-EGPA Study

Sponsor

European EGPA Study Group

Enrollment

100 participants

Start Date

Feb 11, 2026

Study Type

OBSERVATIONAL

Conditions

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Summary

This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Benralizumab 30 mg/ml for people with eosinophilic granulomatosis with polyangiitis (egpa). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBenralizumab 30 mg/ml

Benralizumab administered at a dose of 30 mg every 4 weeks in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. Patients may receive benralizumab as first-line biologic therapy or after previous exposure to mepolizumab. Treatment use, persistence, dosage changes, effectiveness outcomes, and safety events will be assessed during follow-up.